2023-08-15 12:49:49 ET
More on Pharvaris
- Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development
- Pharvaris stock climbs 13% after FDA lifts hold on HAE drug candidate
- Pharvaris adds 58% on positive data from mid-stage hereditary angioedema trial
- Pharvaris downgraded at BofA after FDA clinical hold on HAE candidate
- Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate
- Seeking Alpha’s Quant Rating on Pharvaris
- Earnings data for Pharvaris
For further details see:
Morgan Stanley ups Pharvaris to overweight, citing HAE drug prospects